FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
Genentech secured FDA approval for a venetoclax-plus-acalabrutinib regimen to treat previously untreated chronic lymphocytic leukemia, expanding frontline therapeutic options.
Why it mattersFDA approval of Venclexta plus acalabrutinib for CLL requires hospitals and payors to update formularies.